

## **Listing of Claims**

The following listing of claims replaces all previous listings or versions thereof:

1. (Cancelled)
2. (Previously presented) The isolated peptide of claim 4, wherein the isolated peptide inhibits aminopeptidase A activity.
3. (Cancelled)
4. (Previously presented) An isolated peptide of 50 amino acids or less that selectively binds aminopeptidase A, wherein the isolated peptide comprises a peptide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.
5. – 7. (Cancelled)
8. (Previously presented) The isolated peptide of claim 4, wherein the isolated peptide is operatively coupled to a therapeutic agent.
9. (Previously presented) The isolated peptide of claim 8, wherein said therapeutic agent is a drug, a chemotherapeutic agent, a radioisotope, a pro-apoptosis agent, an anti-angiogenic agent, a hormone, a cytokine, a cytotoxic agent, a cytocidal agent, a cytostatic agent, a peptide, a protein, an antibiotic, an antibody, a Fab fragment of an antibody, a hormone antagonist, a nucleic acid or an antigen.
10. (Currently amended) The isolated peptide of claim 9, wherein the anti-angiogenic agent is selected from the group consisting of thrombospondin, angiostatin, pigment epithelium-derived factor, angiotensin, laminin peptides, fibronectin peptides, plasminogen activator inhibitors, tissue metalloproteinase inhibitors, interferons, interleukin 12, platelet factor 4, IP-10, Gro- $\beta$ , thrombospondin, 2-methoxyoestradiol, proliferin-related protein, carboxamidotriazole, CM101, Marimastat, pentosan polysulphate, angiopoietin 2 (~~Regeneron~~), interferon-alpha, herbimycin A, PNU145156E, 16K prolactin fragment, Linomide, thalidomide, pentoxifylline, genistein, TNP-470, endostatin, paclitaxel, Docetaxel, polyamines, a proteasome inhibitor, a

kinase inhibitor, a signaling peptide, accutin, cidofovir, vincristine, bleomycin, AGM-1470, platelet factor 4 and minocycline.

11. (Previously presented) The isolated peptide of claim 9, wherein said pro-apoptosis agent is selected from the group consisting of etoposide, ceramide sphingomyelin, Bax, Bid, Bik, Bad, caspase-3, caspase-8, caspase-9, fas, fas ligand, fadd, fap-1, tradd, faf, rip, reaper, apoptin, interleukin-2 converting enzyme or annexin V.

12. (Previously presented) The isolated peptide of claim 9, wherein said cytokine is selected from the group consisting of interleukin 1 (IL-1), IL-2, IL-5, IL-10, IL-11, IL-12, IL-18, interferon- $\gamma$  (IF- $\gamma$ ), IF- $\alpha$ , IF- $\beta$ , tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), or GM-CSF (granulocyte macrophage colony stimulating factor).

13. (Previously presented) The isolated peptide of claim 4, wherein said peptide is attached to a molecular complex.

14. (Previously presented) The isolated peptide of claim 13, wherein said complex is a virus, a bacteriophage, a bacterium, a liposome, a microparticle, a magnetic bead, a yeast cell, a mammalian cell or a cell.

15. (Previously presented) The isolated peptide of claim 14, wherein said complex is a virus or a bacteriophage.

16. (Previously presented) The isolated peptide of claim 15, wherein said virus is chosen from the group consisting of adenovirus, retrovirus and adeno-associated virus.

17. (Previously presented) The isolated peptide of claim 15, wherein said virus is further defined as containing a gene therapy vector.

18. (Previously presented) The isolated peptide of claim 14, wherein said peptide is attached to a eukaryotic expression vector.

19. (Previously presented) The isolated peptide of claim 18, wherein said vector is a gene therapy vector.

20. (Cancelled)

21. (Previously presented) A pharmaceutical composition comprising a peptide in accordance with claim 4.

22. – 63. (Cancelled)

64. (Previously presented) The isolated peptide of claim 4, wherein the isolated peptide comprises SEQ ID NO:1.

65. (Previously presented) The isolated peptide of claim 4, wherein the isolated peptide comprises SEQ ID NO:2.

66. (Previously presented) The isolated peptide of claim 4, wherein the isolated peptide comprises SEQ ID NO:3.

67. (Previously presented) The isolated peptide of claim 4, wherein the isolated peptide comprises SEQ ID NO:4.

68. (Previously presented) The isolated peptide of claim 4, wherein the isolated peptide comprises SEQ ID NO:5.

69. (Previously presented) The isolated peptide of claim 4, wherein the isolated peptide comprises SEQ ID NO:6.

70. (Previously presented) The isolated peptide of claim 4, wherein the peptide is 30 amino acids or less in length.

71. (Previously presented) The isolated peptide of claim 70, wherein the peptide is 20 amino acids or less in length.

72. (Previously presented) The isolated peptide of claim 68, wherein the peptide is 20 amino acids or less in length.

73. (Previously presented) The isolated peptide of claim 72, wherein the peptide is 10 amino acids or less in length.

74. – 76. (Canceled)